Biovica announced initiation of the TK IMPACT study, an investigator initiated prospective clinical trial at Washington University of St Louis to evaluate the clinical utility of the company's blood-based biomarker assay DiviTum?TKa on monitoring practices in the care of metastatic breast cancer patients. The study hypothesis is that incorporation of data from DiviTum?TKa measurements into the treatment monitoring of patients receiving standard first line treatment with CDK 4/6 inhibitors plus endocrine therapies, will be associated with the physicians' decision to change usage and/or timing of other routine monitoring tests such as CT scans and nuclear medicine exams. The study will examine care over time of 55 patients that will be tested regularly with DiviTum?TKa.